tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Inmune Bio’s Promising Pipeline and Strategic Positioning Support Buy Rating Despite Recent Challenges
PremiumRatingsInmune Bio’s Promising Pipeline and Strategic Positioning Support Buy Rating Despite Recent Challenges
1M ago
Inmune Bio Submits Manuscript on Alzheimer’s Trial
Premium
Company Announcements
Inmune Bio Submits Manuscript on Alzheimer’s Trial
1M ago
INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia
Premium
The Fly
INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia
1M ago
INmune Bio CEO RJ Tesi retires, David Moss succeeds
PremiumThe FlyINmune Bio CEO RJ Tesi retires, David Moss succeeds
3M ago
INmune Bio reports Q2 EPS ($1.05), consensus (38c)
Premium
The Fly
INmune Bio reports Q2 EPS ($1.05), consensus (38c)
3M ago
INmune Bio Completes Phase I/II Trial for INKmune™
Premium
Company Announcements
INmune Bio Completes Phase I/II Trial for INKmune™
3M ago
INmune Bio Releases Video on Alzheimer’s Trial Results
PremiumCompany AnnouncementsINmune Bio Releases Video on Alzheimer’s Trial Results
3M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
3M ago
INmune Bio announces video detailing findings from Phase 2 MINDFuL trial
Premium
The Fly
INmune Bio announces video detailing findings from Phase 2 MINDFuL trial
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100